Can Molecular Imaging Find a Path to Navigate Evolving Breast Cancer Treatments?-Reference-Cited by-同舟云学术

Can Molecular Imaging Find a Path to Navigate Evolving Breast Cancer Treatments?

Published:2023-03-29 Issue:11 Volume:29 Page:2015-2016
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Linden Hannah M.¹^ORCID,Mankoff David A.²³^ORCID

Affiliation:

1. 1University of Washington Department of Medicine Division of Medical Oncology, Fred Hutchinson Cancer Center Clinical Research Division, Seattle, Washington.

2. 2Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

3. 3Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Abstract

Summary[18F]fluoroestradiol (FES) PET is an FDA-approved imaging biomarker. Like IHC, FES positivity predicts clinical benefit of endocrine therapy. In addition, FES measures the target activity in endocrine agent drug development. A recent study found that whole body tumor heterogeneity of expression predicts clinical benefit, and serial FES monitors estrogen receptor blockade and posttreatment release.See related article by Iqbal et al., p. 2075

Funder

National Cancer Institute

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-23-0393/3295801/ccr-23-0393.pdf

Reference17 articles.

1. [18F]FDG and [18F]FES PET/CT imaging as a biomarker for therapy effect in patients with metastatic ER+ breast cancer undergoing treatment with rintodestrant;Iqbal;Clin Cancer Res,2023

2. Accelerating drug development in breast cancer: new frontiers for ER inhibition;Ferraro;Cancer Treat Rev,2022

3. The quest for improving the management of breast cancer by functional imaging: the discovery and development of 16alpha-[(18)F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review;Katzenellenbogen;Nucl Med Biol,2021

4. Clinical validity of 16alpha-[(18)F]fluoro-17beta-estradiol positron emission tomography/computed tomography to assess estrogen receptor status in newly diagnosed metastatic breast cancer;van Geel;J Clin Oncol,2022

5. Diagnostic accuracy and safety of 16alpha-[(18)F]fluoro-17beta-oestradiol PET-CT for the assessment of estrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study;Chae;The Lancet. Oncology,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PET Imaging of Metabolism, Perfusion, and Hypoxia;The Cancer Journal;2024-05